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Introduction
Several previous epidemiological studies have linked elevated resting heart rate to increased risk of cardiovascular disease and all-cause mortality (1;2). Resting heart rate is known to be a sensitive indicator of the autonomic nervous system,(3) and it is possible that an imbalance between parasympathetic and sympathetic activity might contribute towards the observed association between a raised resting heart rate and type 2 diabetes. Increased sympathetic tone not only elevates resting heart rate, but also amplifies insulin resistance, (4) which might suggest an intermediary role for impaired autonomic nervous activity in the relationship between resting heart rate and type 2 diabetes. Alternatively, metabolic syndrome, abdominal obesity and insulin resistance may activate the sympathetic nervous system, with elevated heart rate being a consequence rather than a cause of the metabolic alterations (5) .
Despite this, the association between elevated resting heart rate and type 2 diabetes remains unclear (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . Some studies suggested an increased risk of type 2 diabetes with higher heart rate (6;7;10;12-17), whereas others found the association to be no longer significant after adjustment for potential confounding factors (8;9;11) . These studies were, however, largely heterogeneous with regards to the strength of the association; some reported a 60-100% increase in the risk (6;7;13-15) and others up to a 5-fold increase (14) in risk with elevated heart rate.
Hence, we conducted a systematic review and meta-analysis of prospective studies that examined the relationship between resting heart rate and type 2 diabetes. Specifically we aimed to: 1) clarify the strength of the association, 2) determine whether there is a doseresponse relationship, and 3) establish whether the association varies by adjustment for potential confounding factors and other study characteristics.
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Methods
Search strategy
We searched the electronic databases PubMed, Embase and Ovid Medline databases up until October 11 th 2013 for prospective studies of resting heart rate and type 2 diabetes risk. We used the following search terms for the search: ("resting heart rate" OR "heart rate" OR "resting pulse") AND "diabetes" with search fields "title/abstract" and "MeSH terms". No language restrictions were imposed. We also examined the reference lists of the studies included in the analysis in an effort to identify additional potentially relevant studies. All retrieved citations were screened by 2 independent reviewers (D.A. and B.H.) and any disagreements were resolved by consensus among authors.
Study selection
Studies were included in the analyses based on the following inclusion criteria: the study had to: 1) have a prospective cohort, case-cohort or nested case-control design from the general population (no studies of high-risk patients with hypertension or cardiovascular disease were included), 2) investigate the association between resting heart rate and risk of type 2 diabetes,
3) present estimates of the relative risk (RR), such as hazard ratios, risk ratios, or odds ratios with the 95% confidence intervals (95% CI), and 4) for the dose-response analysis, a quantitative measure of the heart rate and the total number of cases and person-years or participants had to have been available in the publication. We contacted the authors of two studies (6;7) to obtain more detailed results so the studies could be included in the doseresponse analysis, and received more detailed data from one study (6) .
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Data extraction
We extracted the following data from each study: The first author's last name, publication year, country where the study was conducted, the study name, follow-up period, sample size, gender, age, number of cases, exposure, resting heart rate level, RRs and 95% CIs for the association and variables adjusted for in the analysis.
Statistical methods
We used random effects models to calculate summary RRs and 95% CIs for the highest vs.
the lowest level of resting heart rate and also for the dose-response analysis (18) . The average of the natural logarithm of the RRs was estimated and the RR from each study was weighted by the inverse of its variance and then un-weighted by a variance component which corresponds to the amount of heterogeneity in the analysis. A two-tailed p<0.05 was considered statistically significant. For the two studies which reported results separately for men and women (14) or by treatment group (10), we combined the results using a fixedeffects model to obtain an overall estimate which was used for the main analysis.
The method described by Greenland and Longnecker (19) was used for the doseresponse analysis and study-specific slopes (linear trends) and 95% CIs from the natural logs of the RRs and CIs were computed across categories of resting heart rate. This method requires that the distribution of cases and person-years or non-cases and the level of resting heart rate and RRs with the variance estimates for at least three quantitative exposure categories are known. We estimated the distribution of person-years in studies that did not report these. For one study we divided the total number of participants by four to get the approximate number of participants for each quartile (11) . For four studies (11-13;15) we multiplied the mean or median duration of follow-up by the number of participants in each M A N U S C R I P T
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category to get an estimate of the number of person-years for each category. Importantly, because these estimated numbers are only used as starting points for the glst-iterations they do not affect the estimated dose-response slopes (we also repeated the analyses using slightly different numbers of person-years, but this led to identical results). The median or mean resting heart rate level in each category was assigned to the corresponding relative risk for each study. When resting heart rate was reported as ranges we estimated the midpoint for each category by calculating the average of the lower and upper bound. When the highest or
lowest category was open-ended or had extreme upper cut-off points we assumed the openended interval length to be the same as the adjacent interval. A potential nonlinear doseresponse relationship between resting heart rate and type 2 diabetes was examined using fractional polynomial models (20) . We determined the best fitting second order fractional polynomial regression model, defined as the one with the lowest deviance. A likelihood ratio test was used to assess the difference between the nonlinear and linear models to test for nonlinearity (20) .
Study quality was assessed using the Newcastle-Ottawa scale which measures study quality based on representativeness of the exposed cohort, selection of the non-exposed cohort, ascertainment of exposure, demonstration that the outcome was not present at the start of the study, comparability of cohorts (adjustment or matching for two different risk factors), assessment of outcome, duration of follow-up, and adequacy of follow-up and gives a maximum of nine stars (21) . We grouped studies with 0-3 stars, 4-6 stars, and 7-9 stars for the subgroup analysis.
We assessed heterogeneity between studies using the Q test and I 2 (22) . I 2 is the amount of total variation that is explained by between study variation. I 2 values of approximately 25%, 50% and 75% are considered to reflect low, moderate and high heterogeneity, respectively. Subgroup analyses were conducted to investigate potential M A N U S C R I P T
sources of heterogeneity including duration of follow-up, gender, geographic location, number of cases, study quality, adjustment for confounding factors, and exclusion of subjects using hypertensive or cardiovascular disease medications or with diagnosed cardiovascular disease at baseline.
Publication bias was assessed with Egger's test (23) and the results were considered to indicate publication bias when p<0.10. We conducted sensitivity analyses excluding one study at a time to ensure that the results were not simply due to one large study or a study with an extreme result. Results from these sensitivity analyses are presented excluding the two studies with the largest negative and positive impact on the summary estimates. The statistical analyses were conducted using Stata, version 10.1 software (StataCorp, College
Station, TX, USA).
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Results
Main results
We identified 10 cohort studies of healthy general populations (6-15) that were included in the meta-analysis of resting heart rate and type 2 diabetes (Table 1, Figure 1 ) and these included a total of 5,628 cases and 119,915 participants. Two studies (16;17) of hypertensive patients and cardiovascular disease patients were excluded from the analysis. The summary RR for high vs. low resting heart rate was 1.83 (95% CI: 1.28-2.60, n=7) (Supplementary (11) was excluded. Heterogeneity was reduced when both of these outlying studies were excluded (11;14) , but the summary estimate remained similar, summary RR=1.17 (95% CI:
1.09-1.26, I 2 =59%, p heterogeneity =0.02). There was no evidence of publication bias with Egger's test, p=0.42, although the number of studies was low. There was no substantial evidence of asymmetry in the funnel plot (Supplementary Figure 2) . The nonlinear dose-response analysis requires at least three categories of resting heart rate, so studies that only reported a continuous estimate could not be included, so in total six studies were included in the nonlinear dose-response analysis (11) (12) (13) (14) (15) . There was evidence of a nonlinear association between resting heart rate and risk of type 2 diabetes, p nonlinearity <0.0001, with the slope M A N U S C R I P T
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leveling off at higher levels ( Figure 2b ). Study quality as assessed by the Newcastle-Ottawa scale was in general high with a range from 5-9 stars out of 9 possible and a median of 7.5 stars (Supplemental Table 2 ) and there was no evidence of heterogeneity by study quality scores (Table 2) .
Subgroup, sensitivity and meta-regression analyses
In subgroup and meta-regression analyses we found no significant heterogeneity between subgroups when studies were stratified by gender, duration of follow-up, geographic location, or study size (Table 2) , although the associations did not always persist across subgroups.
Further subgroup analyses according to whether studies had adjusted for confounding factors didn't reveal significant heterogeneity between strata, although associations were not always statistically significant. There was also no significant heterogeneity between subgroups of studies with or without exclusion of hypertensive medication users, cardiovascular medication users or persons with prevalent cardiovascular disease at baseline (Table 2 ). For one study reporting results from a randomized trial with three groups (placebo, metformin treatment, and lifestyle intervention) (10) we conducted a further sensitivity analysis using only the results from the placebo group in the meta-analysis, but the results remained similar, summary RR=1.20 (95% CI: 1.06-1.35, I 2 =93%, p heterogeneity <0.0001).
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Discussion: To our knowledge this is the first meta-analysis on the relationship between resting heart rate and risk of type 2 diabetes. We found a high vs. low resting heart rate was associated with an 83% increase in the RR of type 2 diabetes. Moreover the dose-response analysis showed the RR increased 19% for every 10 beats per minute increment in resting heart rate. The association appeared to be nonlinear, and leveled off at higher values of resting heart rate.
Several biological mechanisms could explain the association between resting heart rate and type 2 diabetes. An elevated resting heart rate may reflect an imbalance in the autonomic nervous system favouring sympathetic activation. Indeed, sympathetic overactivity has been linked with reduced insulin sensitivity, high blood pressure, obesity, inflammation and the metabolic syndrome (12;24-27) , all of which increases the risk of type 2 diabetes. Further, the pancreas is heavily innervated by parasympathetic nerve fibers, which stimulate β-cells of the pancreas to release insulin in response to increasing blood glucose levels. On the other hand sympathetic stimulation inhibits the secretion of insulin from pancreatic β-cells. Moreover, some evidence proposes that sympathetic activation might contribute to insulin resistance by inducing haemodynamic and cellular effects (28) .
Sympathetic activation causes vasoconstriction and decreases skeletal muscle blood flow, leading to impaired glucose uptake in skeletal muscle (29) . Further, epinephrine causes hyperglycaemia by reducing the insulin-mediated glucose uptake in skeletal muscle cells, while β-adrenergic receptor blockade seems to abolish this effect (30) . Sympathetic overactivity also stimulates the renin-angiotensin-aldosterone system, which increases heart rate and may be implicated in insulin resistance (31;32) . In support of this are results from some randomized trials which have shown that patients treated with ACE inhibitors or angiotensin receptor blockers have a lower risk of type 2 diabetes compared to control patients (33-36), however, not all studies have been consistent (37) .
Some evidence reported that chronic sympathetic overactivity may facilitate the development of obesity by downregulating the β-adrenoceptor-mediated thermogenic response (38;39) . The relationship between sympathetic activation and insulin resistance may also be reciprocal. Elevated glucose levels, even in the non-diabetic range can damage peripheral nerve fibers, leading to increased sympathetic activity and reduced parasympathetic control (40) (41) (42) . Thus, it is possible that an elevated resting heart rate could be a consequence, and equally, a marker of insulin resistance. In this meta-analysis, the association between resting heart rate was attenuated in subgroup analysis of the studies that adjusted for baseline glucose or HOMA-IR. These findings suggest that baseline glucose and/or insulin resistance accounts for part, though not all of the association, as the positive relationship between elevated resting heart rate and type 2 diabetes persisted in the studies with such adjustment. The potential mechanism that could explain the nonlinear association between resting heart rate and type 2 diabetes are yet to be fully clarified.
Some potential limitations of this meta-analysis should be mentioned. There was high heterogeneity both in the high vs. low analysis and the dose-response analysis, although this appeared to be largely explained by one (14) and two (11;14) studies , respectively. When both studies were excluded the heterogeneity was substantially reduced in the high vs. low analysis and it was lower in the dose-response analysis as well. In this meta-analysis it is possible that unmeasured or residual confounding may have influenced the association between elevated resting heart rate and type 2 diabetes. Indeed, high resting heart rate may be associated with other risk factors for type 2 diabetes including obesity, hypertension, smoking, and a sedentary lifestyle (12;43). Nevertheless, many of the studies included in this meta-analysis adjusted for known confounding factors such as age, BMI, smoking, and physical activity. The results persisted in most, but not all subgroup analyses, possibly due to few studies in some strata. However, more importantly we found no evidence of M A N U S C R I P T
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heterogeneity between these subgroups with meta-regression analyses. Use of antihypertensive and cardiovascular disease medications can affect heart rate and could potentially have influenced the results, however, the results persisted in several subgroup analyses where persons using such medications and/or persons with cardiovascular disease at baseline had been excluded.
Publication bias may also have affected the results, albeit, in this study we found no evidence of publication bias with the statistical tests and there was no evidence of asymmetry when inspecting the funnel plots, although the number of studies was moderate.
Our meta-analysis has several strengths. Combining the evidence from all available studies increased the statistical power to detect an association between elevated resting heart rate and type 2 diabetes. We conducted high vs. low analyses, and linear and nonlinear doseresponse analyses to clarify the strength and the shape of the dose-response relationship between resting heart rate and type 2 diabetes. We also conducted a number of subgroup and sensitivity analyses and the association persisted across most strata of study characteristics.
Lastly the study quality was high and ranged from 5-9, with a median of 7.5 out of 9 stars.
In conclusion, the current meta-analysis found a positive association between resting heart rate and risk of type 2 diabetes. As a non-invasive marker, the resting heart rate may have potential in the clinical setting, particularly for interventions aimed at reducing the risk of type 2 diabetes. Additional studies are needed to disentangle the causal mechanisms that may be responsible for the association between resting heart rate and type 2 diabetes. n denotes the number of studies.
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1 P for heterogeneity within each subgroup, 2 P for heterogeneity between subgroups with meta-regression analysis, 3 P for heterogeneity between men and women (studies with genders mixed were excluded) 4 The number of studies is not equal to the total because some studies reported both on men and women 
